amphotericin-b and Myocardial-Ischemia

Invasive aspergillosis in immuncompromised patients occurs frequently. Surgical therapy in combination with chemotherapy with amphotericin B and itraconazole is standard therapy. We describe a heart transplant recipient with invasive Aspergillus fumigatus infection in the lung, which was treated successfully with voriconazole after systemically high-dose intravenous therapy with amphotericin B failed.

Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Heart Transplantation; Humans; Lung Diseases, Fungal; Middle Aged; Myocardial Ischemia; Postoperative Complications; Pyrimidines; Tomography, X-Ray Computed; Triazoles; Voriconazole

Pulmonary mucormycosis is rare in solid organ transplant recipients. Only one case has been reported previously in a cardiac allograft recipient. However, the Rhizopus species in that study was not identified. We report a case of successful surgical treatment of pulmonary cavitary mucormycosis due to Rhizopus rhizopodiformis in a cardiac allograft transplant recipient. A review of the literature on pulmonary mucormycosis occurring in solid organ transplant recipients is also presented.

Topics: Amphotericin B; Antifungal Agents; Heart Transplantation; Humans; Lung Abscess; Lung Diseases, Fungal; Male; Middle Aged; Mucormycosis; Myocardial Ischemia; Rhizopus; Transplantation, Homologous